Comparing the clinical performance and cost efficacy of [

Decision Support Techniques Edetic Acid Fluorine Radioisotopes Gallium Isotopes Gallium Radioisotopes Humans Male Markov Chains Neoplasm Recurrence, Local / diagnostic imaging Niacinamide / analogs & derivatives Oligopeptides Positron Emission Tomography Computed Tomography / methods Prostatic Neoplasms / diagnostic imaging Radiopharmaceuticals Retrospective Studies
Markov chain analysis PET/CT PSMA Positron emission tomography Recurrent prostate cancer

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 23 08 2021
accepted: 05 11 2021
pubmed: 14 11 2021
medline: 5 10 2022
entrez: 13 11 2021
Statut: ppublish

Résumé

Amongst others, [ Two hundred and forty-four patients undergoing PSMA PET/CT for rPC were retrospectively analysed for this study (one hundred and twenty two with each radiopharmaceutical) to generate rates of PET positivity, negativity and unclear findings. Patients underwent follow-up to determine the rate of additional examinations and to confirm PET findings. A Markov chain decision analysis was implemented to model clinical decision-making processes and to analyse clinical performance of the two tracers. We determine their clinical cost efficacies using cost data from several countries where both radiotracers are in routine use. The PET positivity rate was non-significantly higher for [ The analysis reveals a non-significantly higher PET positivity rate for [

Identifiants

DOI: 10.1007/s00259-021-05620-9 PMID: 34773473 PMC: PMC9525363
pubmed: 34773473
doi: 10.1007/s00259-021-05620-9
pii: 10.1007/s00259-021-05620-9
pmc: PMC9525363
doi:

Substances chimiques

Fluorine Radioisotopes 0
Gallium Isotopes 0
Gallium Radioisotopes 0
Oligopeptides 0
PSMA-1007 0
Radiopharmaceuticals 0
gallium 68 PSMA-11 0
Niacinamide 25X51I8RD4
Edetic Acid 9G34HU7RV0
Fluorine-18 GZ5I74KB8G

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4252-4261

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Lancet Oncol. 2021 Apr;22(4):422-423
pubmed: 33676603
PLoS One. 2020 Oct 7;15(10):e0240215
pubmed: 33027310
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):226-234
pubmed: 29101444
Med Decis Making. 2005 Sep-Oct;25(5):511-9
pubmed: 16160207
J Nucl Med. 2021 Feb;62(2):208-213
pubmed: 32817141
Theranostics. 2020 Feb 10;10(7):3254-3262
pubmed: 32194866
Theranostics. 2020 Jan 1;10(1):1-16
pubmed: 31903102
J Nucl Med. 2019 Jun;60(6):786-793
pubmed: 30530831
EJNMMI Res. 2021 Jan 6;11(1):3
pubmed: 33409930
BMJ. 2013 Mar 25;346:f1049
pubmed: 23529982
J Nucl Med. 2020 Jan;61(1):51-57
pubmed: 31253741
J Nucl Med. 2021 Feb;62(2):149-155
pubmed: 33443068
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
Clin Exp Metastasis. 2020 Apr;37(2):305-312
pubmed: 32064552
Am Soc Clin Oncol Educ Book. 2018 May 23;38:355-362
pubmed: 30231323
J Nucl Med. 2019 Apr;60(4):511-516
pubmed: 30190303
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):917-926
pubmed: 32544574
Lancet. 1999 Nov 27;354(9193):1896-900
pubmed: 10584742
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2925-2934
pubmed: 33543325
Nuklearmedizin. 2020 Feb;59(1):33-34
pubmed: 31766065
Eur Urol. 2021 Mar;79(3):413-418
pubmed: 33341285
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4483-4494
pubmed: 34120201
MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1473-1480
pubmed: 33056955
J Mark Access Health Policy. 2020 Feb 15;8(1):1717030
pubmed: 32158523
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2690-2691
pubmed: 33742238
J Nucl Med. 2021 Sep 1;62(9):1252-1257
pubmed: 33547214
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2055-2061
pubmed: 30027419
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
PLoS One. 2019 Feb 22;14(2):e0211633
pubmed: 30794569
BMC Med Res Methodol. 2003 Nov 10;3:25
pubmed: 14606960
JAMA. 2017 Feb 21;317(7):705-707
pubmed: 28241335
J Nucl Med. 2019 Dec;60(12):1736-1742
pubmed: 31028165
Nucl Med Biol. 2020 Jan - Feb;80-81:24-31
pubmed: 32004935
Nat Rev Drug Discov. 2006 Jan;5(1):27-36
pubmed: 16485344
Pharmacoeconomics. 1998 Apr;13(4):397-409
pubmed: 10178664
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):486-95
pubmed: 23179945
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):160-167
pubmed: 31628514
J Nucl Med. 2017 Dec;58(12):1972-1976
pubmed: 28747524
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2978-2989
pubmed: 33550425

Auteurs

Ian Alberts (I)

Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland. ian.alberts@insel.ch.
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. ian.alberts@insel.ch.

Clemens Mingels (C)

Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland.
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Helle D Zacho (HD)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital, Hobrovej 18-22, DK-9000, Aalborg, Denmark.

Sabine Lanz (S)

Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland.
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Heiko Schöder (H)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Axel Rominger (A)

Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland.
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Marcel Zwahlen (M)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Ali Afshar-Oromieh (A)

Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland.
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Sciences de l'information › Informatique › Informatique médicale › Applications de l'informatique médicale › Techniques d'aide à la décision › Comparing the clinical performance and cost...
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides acycliques › Acide édétique › Comparing the clinical performance and cost...
questionsmedicales.fr › Produits chimiques inorganiques › Isotopes › Radio-isotopes › Radio-isotopes du fluor › Comparing the clinical performance and cost...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Gallium › Isotopes du gallium › Comparing the clinical performance and cost...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Gallium › Isotopes du gallium › Radio-isotopes du gallium › Comparing the clinical performance and cost...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Comparing the clinical performance and cost...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Processus stochastiques › Chaines de Markov › Comparing the clinical performance and cost...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Comparing the clinical performance and cost...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Acides nicotiniques › Nicotinamide › Comparing the clinical performance and cost...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Oligopeptides › Comparing the clinical performance and cost...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Comparing the clinical performance and cost...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Comparing the clinical performance and cost...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › Comparing the clinical performance and cost...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Comparing the clinical performance and cost...